Esra ADEMOĞLU, Erdal DİLEKÇİ, Zehra CANDAN, Suheyla GORAR, Mutlu NİYAZOĞLU, Ayşe ÇARLIOĞLU, Faruk YILDIZ, İdris BAYDAR, Abdulmuttalip ASLAN

Is circulating survivin altered in acromegaly?

Acromegaly is a chronic disorder which is characterized by growth hormone (GH) excess. In most of cases, GH hypersecretion is derived from somatotroph cell tumors. Survivin is a member of apoptosis protein family, which was recently showed to be expressed in tissue samples of different benign and malignant human tumors. This study is intended to determine circulating levels of survivin in newly diagnosed acromegaly patients with somatotroph adenomas. 19 newly diagnosed acromegaly patients with somatotroph adenomas were inclu-ded in the study. Concurrently, 19 healthy individuals were included as control group. Serum survivin levels, GH, insulin like growth factor-1 (IGF-1) and, some other biochemical parame-ters as fasting glucose, creatinine, alanine aminotransferase, cholesterol, triglyceride, high den-sity lipoprotein cholesterol, low density lipoprotein cholesterol were measured in each subject. Correlation analysis was performed between survivin and GH, IGF-1. Serum survivin levels tended to be higher in acromegaly group, but this was not reach statistical significance (p>0.05). Serum survivin levels were comparable among acromegaly patients and controls. Neither GH nor IGF-1 correlated with serum survivin. Larger scale studies are needed concerning the circulating levels of survivin in patients with acromegaly.

PDF

___

Chesnokova V, Melmed S. Pituitary senescence: the evolving role of PTTG. Moll Cell Endo-crinol. 2010;15;326(1-2):55-9.

Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009;119(11):3189-3202.

Duffy MJ, O’Donovan N, Brennan DJ, et al. Survivin: a promising tu-mor biomarker. Cancer Lett. 2007;249(1):49-60.

Driscoll L, Linehan R, Clynes M. Survivin: role in normal cells and in pathological conditions. Curr Cancer Drug Targets. 2003;3(2):131-152.

Shinohara E, Gonzalez A, Massion PP, et al. Nuclear surviving predicts recur-rence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer. 2005;103(8):1685-92.

Ma X, Wu X, Liu XliY, Liu L. Prognostic significance of survivin in breast cancer: meta-analysis. Breast. 2014;20(5):514-24.

Satoh K, Kaneko K, Hirota M, et al. Expression of sur-vivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92(2):271-8.

Hernandez JM, Farma JM, Coppola D, et al. Expression of antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10(3):188-93.

Kappler M, Rot S, Taubert H, et al. The effects of knockdown of wild-type survivin, survivin-2B or survivin-3 on the radio-sensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. Cancer Gene Therapy. 2007;14:994-1001.

McKenzie JA, Grossman D. Role of the apoptotic and mitotic regulator survivin in melano-ma. Anticancer Res. 2012;32(2):397-404.

Grossman D, McNiff JM, Li F, et al. Expression and targeting of the apoptosis inhibi-tor, surviving in human melanoma. J Invest Dermatol. 1;113(6):1076-81

Purroy N, Abrisqueta P, Carabia J, et al. Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein. Leukemia. 2014;28(10):1993-2004.

Lui R, Mitchell DA. Survivin as an immunotherapeutic target for adult and pediatric malig-nant brain tumors. Cancer Immunol Immunother. 2010;59(2):183-93.

Azuhata T, Scott D, Takamizawa S, et al. The inhibi-tor of apoptosis protein survivin is associated with high-risk behavior of neuroblasto-ma. J Pediatr Surg. 2001;36(12):1785-91.

Wasko R, Jankowska A, Waligorska-Stachura J, et al. Survivin expression in pituitary adenomas. Neuro Endocrinol Lett. 2005;26(3):209-12.

Formosa R, Gruppetta M, Falzon S, et al. Expression and clinical significance of Wnt players and survivin in Pituitary tumors. Endocr Pathol. 2012;23(2):12331.

Jankowska A, Wasko R, Waligorska-Stachura J, et al. Survivin products in pituitary tumors. Neuro Endocrinol Lett. 2008;29(6):1033-7.

Zhang X, Horwitz GA, Prezant TR, et al. Structure, expression and function of human pituitary tumor-transforming gene (PTTG). Mol Endocrinol. 1999;13(1):156-66.

Waligorska-Stachura J, Andrusiewicz M, Sawicka-Gutaj N, et al. Evaluation of sur-vivin splice variants in pituitary tumors. Pituitary. 2015;18(3):410-6.

Wasko R, Waligorska-Stachura J, Jankowska A, et al. Coex-pression of survivin and PCNA in pituitary tumors and normal pituitary. Neuro Endocrinol Lett. 2009;30(4):477-81.

Dong H, Qian D, Wang Y, et al. Survivin expression and serum levels in pancreatic cancer. World J Surg Oncol. 2015;28(13):189.

Ren YQ, Zhang HY, Su T, et al. Clinical significance of serum survivin in patient with pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci. 2014;18(20):3063-8.

Guney N, Soydine HO, Derin D, et al. Serum and urine survivin levels in breast cancer. Med Oncol. 2006;23(3):335-9.

Goksel G, Taneli F, Uslu R, et al. Serum her2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. J Int Med Res. 2007;35(2):165-72.

Tas F, Duranyildiz D, Argon A, et al. Serum bcl-2 and survivin levels in melanoma. Melanoma Res. 2004;14(6):543-6.

Naumnik W, Nilklinska W, Ossolinka M, et al. Serum levels of HMGB1, survivin and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Fo-lia Histochem Cytobiol. 2009;47(4):703-9.

Goricar K, Kovac V, Franko A, et al. Serum survivin levels and out-come of chemotherapy in patients with malignant mesothelioma. Dis Markers. 2015;2015:316739.

Hu YM, Li J, Yu LC, et al. Survivin mRNA level in blood predict the efficacy of neoadjuvant chemotherapy in patients with stage IIIA-N2 non-small cell lung cancer. Pathol Oncol Res. 2015;21(2):257-65.

Holdaway IM, Bolland MJ, Gamble GD. 2008 A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008 ;159:89 -95.